Behring

CSL Behring is the rare-disease and specialty biotherapeutics business within CSL, focused on plasma-derived, recombinant, and gene therapies for serious and rare conditions. The company markets a broad portfolio across immunology, hematology, cardiovascular and renal, respiratory, and transplant medicine, including therapies for hereditary angioedema, hemophilia, immunodeficiencies, and alpha-1 antitrypsin deficiency. Its commercial base is anchored by a large global plasma-fractionation and manufacturing network that is vertically integrated with CSL Plasma. In addition to its marketed products, CSL Behring continues to advance late-stage and earlier-stage programs such as garadacimab, clazakizumab, complement inhibitors, and inhaled immunoglobulin approaches. The business operates globally and is one of CSL's core operating segments.